Reducing mortality in sepsis: new directions

Considerable progress has been made in the past few years in the development of therapeutic interventions that can reduce mortality in sepsis. However, encouraging physicians to put the results of new studies into practice is not always simple. A roundtable was thus convened to provide guidance for clinicians on the integration and implementation of new interventions into the intensive care unit (ICU). Five topics were selected that have been shown in randomized, controlled trials to reduce mortality: limiting the tidal volume in acute lung injury or acute respiratory distress syndrome, early goal-directed therapy, use of drotrecogin alfa (activated), use of moderate doses of steroids, and tight control of blood sugar. One of the principal investigators for each study was invited to participate in the roundtable. The discussions and questions that followed the presentation of data by each panel member enabled a consensus recommendation to be derived regarding when each intervention should be used. Each new intervention has a place in the management of patients with sepsis. Furthermore, and importantly, the therapies are not mutually exclusive; many patients will need a combination of several approaches – an 'ICU package'. The present article provides guidelines from experts in the field on optimal patient selection and timing for each intervention, and provides advice on how to integrate new therapies into ICU practice, including protocol development, so that mortality rates from this disease process can be reduced.

[1]  J. E. Carceller Practice parameters for hemodynamic support of sepsis in adult patients in sepsis , 1999 .

[2]  C. Sprung,et al.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .

[3]  J. Vincent,et al.  Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. , 1999, Critical care medicine.

[4]  Gordon R. Bernard,et al.  Treating patients with severe sepsis. , 1999, New England Journal of Medicine.

[5]  José A Fernández,et al.  Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications , 2000, Critical care medicine.

[6]  G. Chrousos,et al.  Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. , 2002, American journal of respiratory and critical care medicine.

[7]  I. Chaudry,et al.  Adrenal insufficiency during the late stage of polymicrobial sepsis , 1999, Critical care medicine.

[8]  R. Waldrop,et al.  Critical care provided in an urban emergency department. , 1998, The American journal of emergency medicine.

[9]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[10]  Derek C. Angus,et al.  Epidemiology of sepsis: An update , 2001, Critical care medicine.

[11]  R. Balk,et al.  SEVERE SEPSIS AND SEPTIC SHOCK , 2000 .

[12]  G. Koch,et al.  Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial , 1995 .

[13]  M Schetz,et al.  Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.

[14]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[15]  B. Bistrian,et al.  Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.

[16]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[17]  D. Powars,et al.  Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  P. Pelosi,et al.  A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. , 1996, The New England journal of medicine.

[19]  R. Lefering,et al.  Steroid controversy in sepsis and septic shock: a meta-analysis. , 1995, Critical care medicine.

[20]  S. Nasraway,et al.  Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. , 1995, JAMA.

[21]  P. Bollaert,et al.  Reversal of late septic shock with supraphysiologic doses of hydrocortisone. , 1998, Critical care medicine.

[22]  M. Haller,et al.  Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. , 1999, Critical care medicine.

[23]  Véronique Sébille,et al.  Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock , 2002 .

[24]  C. Sprung,et al.  Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. , 1998, Critical care medicine.

[25]  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock , 2003, Current infectious disease reports.

[26]  L. Thijs,et al.  Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma , 2001, Intensive Care Medicine.

[27]  Arthur S Slutsky,et al.  Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. , 1999, JAMA.

[28]  A. Chang,et al.  Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. , 1987, The Journal of clinical investigation.

[29]  K. Steinberg,et al.  Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. , 1995, JAMA.

[30]  M. Blombäck,et al.  Protein C, Protein S and c4b-Binding Protein in Severe lnfection and Septic Shock , 1991, Thrombosis and Haemostasis.

[31]  J. Helterbrand,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis , 2003 .

[32]  Arthur S Slutsky,et al.  Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. , 1997, The Journal of clinical investigation.

[33]  H. Nguyen,et al.  Critical care in the emergency department: A physiologic assessment and outcome evaluation. , 2000, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[34]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[35]  C. Carvalho,et al.  Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. , 1998, The New England journal of medicine.

[36]  D. Cook,et al.  Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. , 1995, Critical care medicine.

[37]  J. McCutchan,et al.  Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. , 1983, The New England journal of medicine.

[38]  Lessening the punch of heparin-induced thrombocytopenia. , 2002, Chest.

[39]  T. Butler,et al.  Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients , 2001, Critical care medicine.

[40]  G. Bernard,et al.  Airway and lung in sepsis , 2001, Intensive Care Medicine.

[41]  J. Martin,et al.  National Vital Statistics Reports , 2002 .

[42]  D. Annane,et al.  A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. , 2000, JAMA.

[43]  G. Van den Berghe,et al.  Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. , 1999, The Journal of clinical endocrinology and metabolism.

[44]  R. Bone Gram-negative sepsis: a dilemma of modern medicine , 1993, Clinical Microbiology Reviews.

[45]  C. Hinds,et al.  Elevation of systemic oxygen delivery in the treatment of critically ill patients. , 1994, The New England journal of medicine.

[46]  D. Schoenfeld,et al.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.

[47]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[48]  G. Van den Berghe,et al.  A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. , 2000, The Journal of clinical endocrinology and metabolism.

[49]  J. Vincent Need for intensivists in intensive-care units , 2000, The Lancet.

[50]  J. Helterbrand,et al.  Low levels of protein C are associated with poor outcome in severe sepsis. , 2001, Chest.

[51]  A. Morris,et al.  Care A H Morris environments Decision support and safety of clinical , 2002 .

[52]  P. Pelosi,et al.  A Trial of Goal-Oriented Hemodynamic Therapy in Critically Ill Patients , 1995 .

[53]  C. Esmon,et al.  The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. , 2000, Blood.